Literature DB >> 16644569

Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.

M P W A Houben1, K K H Aben, J L J M Teepen, A Y N Schouten-Van Meeteren, C C Tijssen, C M Van Duijn, J W W Coebergh.   

Abstract

Time trends in the incidence of glioma may reflect changes in the prevalence of environmental risk factors for glioma. We therefore investigated trends in the incidence of childhood and adult glioma in The Netherlands from 1989 to 2003. We used population-based incidence data from the Netherlands Cancer Registry. We calculated European standardised incidence rates for glioma, and stratified for age, gender and glioma subgroups. Changes in the incidence were estimated by calculating the Estimated Annual Percentage Change. Similar to other countries, the overall incidence of glioma was fairly stable in The Netherlands during the period 1989 to 2003, for both children and adults. In adult astrocytic glioma, a significantly increasing incidence of high-grade astrocytoma was balanced by simultaneous decreases of low-grade astrocytoma, astrocytoma with unknown malignancy grade and glioma of uncertain histology. Most of these time trends can be explained by improving detection and diagnostic precision. Stable incidence rates of adult and childhood glioma suggest that no major changes in environmental risk factors have occurred, which influenced the incidence of glioma in the studied period.

Entities:  

Mesh:

Year:  2006        PMID: 16644569     DOI: 10.1080/02841860500543190

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  Relative survival of patients with supratentorial low-grade gliomas.

Authors:  Nicolas R Smoll; Oliver P Gautschi; Bawarjan Schatlo; Karl Schaller; Damien C Weber
Journal:  Neuro Oncol       Date:  2012-07-06       Impact factor: 12.300

2.  Incidence and relative survival of anaplastic astrocytomas.

Authors:  Nicolas R Smoll; Brett Hamilton
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 12.300

3.  Clinical and prognostic significance of HIF-1α in glioma patients: a meta-analysis.

Authors:  Qi Liu; Peicheng Cao
Journal:  Int J Clin Exp Med       Date:  2015-12-15

4.  Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component.

Authors:  Miguel Torres-Martín; Carolina Peña-Granero; Fernando Carceller; Manuel Gutiérrez; Rommel R Burbano; Giovanny R Pinto; Javier S Castresana; Bárbara Melendez; Juan A Rey
Journal:  Mol Cytogenet       Date:  2014-01-06       Impact factor: 2.009

5.  Evaluation of an online tool about the expected course of disease for glioblastoma patients-A qualitative study.

Authors:  Eva van Diest; Wendy H Oldenmenger; Marit Eland; Walter Taal
Journal:  Neurooncol Pract       Date:  2022-05-04

6.  Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study.

Authors:  Conor S Ryan; Young J Juhn; Harsheen Kaur; Chung-Il Wi; Euijung Ryu; Katherine S King; Daniel H Lachance
Journal:  Neurooncol Pract       Date:  2019-12-07

7.  The Evangelismos hospital central nervous system tumor registry: Analysis of 1414 cases (1998-2009).

Authors:  George Stranjalis; Theodosis Kalamatianos; Lampis C Stavrinou; Dimitris Mathios; Christos Koutsarnakis; Chara Tzavara; Maria Loufardaki; Despina Protopappa; Theodore Argyrakos; Dimitra P Rontogianni; Damianos E Sakas
Journal:  Surg Neurol Int       Date:  2013-02-27

Review 8.  Glioma surgery in eloquent areas: can we preserve cognition?

Authors:  Djaina Satoer; Evy Visch-Brink; Clemens Dirven; Arnaud Vincent
Journal:  Acta Neurochir (Wien)       Date:  2015-11-14       Impact factor: 2.216

9.  Effect of artesunate on apoptosis and autophagy in tamoxifen resistant breast cancer cells (TAM-R).

Authors:  Xiaoqing Ding; Wei Yue; Haiyan Chen
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.